The immune system is made up of a complex team of players that detect and destroy disease-causing agents, such as bacteria and viruses. Similarly, this system may eliminate damaged cells, such as cancer cells. One way the immune system finds and destroys invaders is with antibodies. Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAbs) to bind monospecifically to certain cells or proteins. The objective is that this treatment will stimulate the patient's immune system to attack those cells. Different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1. Manufacturers are focusing on developing drugs belonging to various classes in order to treat variety of diseases ranging from cancer to rare diseases. Monoclonal antibody coupled with chemotherapy agents is becoming a viable treatment option to treat various cancers. Also, there was a boost in the development of monoclonal antibody therapeutics for the treatment of COVID-19 in the year 2020
Market Dynamics
Increasing adoption of growth strategies, such as authorization by key regulatory authorities in the market to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in February 2022, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for a new monoclonal antibody, bebtelovimab manufactured by Lilly, a pharmaceutical company for the treatment of COVID-19 that retains activity against the omicron variant.
Key features of the study:
- This report provides in-depth analysis of the global monoclonal antibody therapeutics market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global monoclonal antibody therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study are Pfizer Inc., Novartis AG, Bayer AG, Sanofi, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Merck KGaA, GSK plc., AbbVie Inc., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., AstraZeneca, AbCellera Biologics Inc., Molecular Depot LLC, DAIICHI SANKYO COMPANY, LIMITED., Abbott, Biogen, Thermo Fisher Scientific, Inc., Cell Signaling Technology, Inc, Intas Pharmaceuticals Ltd., Avantor Inc., UCB S.A., Merus N.V., GENEXTGENOMICS.COM, Biogenuix
- Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global monoclonal antibody therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global monoclonal antibody therapeutics market
Detailed Segmentation:
- Global Monoclonal Antibody Therapeutics Market, By Source:
- Human
- Chimeric
- Murine
- Humanized
- Global Monoclonal Antibody Therapeutics Market, By Application:
- Cancer
- Autoimmune Disease
- Hematological Disease
- Infectious Disease
- Others
- Global Monoclonal Antibody Therapeutics Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Monoclonal Antibody Therapeutics Market, By Region:
- North America
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Pfizer Inc.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Bayer AG
- Sanofi
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Merck KGaA
- GSK plc.
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- AstraZeneca
- AbCellera Biologics Inc.
- Molecular Depot LLC
- DAIICHI SANKYO COMPANY, LIMITED.
- Abbott
- Biogen
- Thermo Fisher Scientific, Inc.
- Cell Signaling Technology, Inc
- Intas Pharmaceuticals Ltd.
- Avantor Inc.
- UCB S.A.
- Merus N.V.
- GENEXTGENOMICS.COM
- Biogenuix
“*” marked represents similar segmentation in other categories in the respective section.
